References
Higashida RT, Furlan AJ, Roberts H, et al, for the Technology Assessment Committees of the American Society of Interventional and Therapeutic Neuroradiology and the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.Stroke 2003; 34: e109-e137.
Yoneyama T, Nakano S, Kawano H, et al. Combined direct percutaneous transluminal angioplasty and low-dose native tissue plasminogen activator therapy for acute embolic middle cerebral artery trunk occlusion.AJNR Am J Neuroradiol 2002; 23: 277–81.
The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study.Stroke 2000; 31: 601–9.
Cecena FA, Hoelzinger DH, Miller JA, Abu-Shakra S. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions.J Interv Cardiol 1999; 12: 355–61.
Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.Lancet 2001; 357: 1905–14.
Eckert B, Koch C, Thomalla G, Roether J, Zeumer H. Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator: report of 3 cases.Stroke 2002; 33: 1424–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Pace, S., Scheggi, V. Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio >-2.0. Int Emergency Med 1, 250–252 (2006). https://doi.org/10.1007/BF02934752
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02934752